Our Clients
CeeTox’s proprietary in Vitro screens are utilized by bio/pharmaceutical, chemical, nutraceutical and government entitities, and continually demonstrates the value of its technology to their clients’ discovery efforts.
Cytorex Biosciences, Inc.
Weston, Florida
CeeTox had an opportunity to work with Cytorex’s proprietary compound Cytoreg®, a great innovation in the fight against cancer. The testing performed by CeeTox, in rat hepatoma (liver cancer), normal hepatocytes (liver), and normal kidney cells, indicated a distinctive cytotoxic activity of Cytoreg® in cancer cells. The CeeTox results were included in the preclinical data package evaluated by the National Cancer Institute, and allowed Cytorex to reach a collaboration agreement with the NCI, to develop the Cytoreg® program as a potential treatment for glioblastoma multiforme (brain cancer).
Vertex Pharmaceuticals, Inc.
Cambridge, Massachusetts
“We began collaborating with CeeTox in 2006. Incorporating CeeTox’s technology into our drug discovery efforts is helping us to select the best compounds for clinical testing from our discovery efforts, as well as select initial doses for evaluation in clinical trials.”
Technology Manager, Program Management and Strategic Planning, Vertex Pharmaceuticals, Inc.
Alliances/Collaborations
CeeTox works closely with scientists and technology partners to advance new chemical entities for the drug development market.
Argutus Medical
Dublin, Ireland
Argutus Medical Ltd. was formed in July 2008 as a spin out company from Biotrin Internation Ltd to give enhanced focus to expanding its portfolio of test kits. Argutus Medical is a world leader in developing and manufacturing novel organ injury tests for use in the detection of early, acute damage to the kidney, liver and pancreas. These eay-to-use microtitre plate assay kits have particular use in preclinical pharmaceutical R&D, Human phase I, II and III clinical trials, and hospital diagnostics. CeeTox is a preferred reference laboratory for Argutus’ novel acute kidney injury (AKI) biomarker panel.